Targeted therapy in advanced desmoid tumors: Current perspectives

Q4 Medicine Forum of Clinical Oncology Pub Date : 2020-12-01 DOI:10.2478/fco-2019-0023
Amrallah A. Mohammed, Hani El-Tanni, H. M. El-Khatib
{"title":"Targeted therapy in advanced desmoid tumors: Current perspectives","authors":"Amrallah A. Mohammed, Hani El-Tanni, H. M. El-Khatib","doi":"10.2478/fco-2019-0023","DOIUrl":null,"url":null,"abstract":"Abstract Background Desmoid tumors/aggressive fibromatosis (DTs/AF) are cytological bland fibrous neoplasms originating from the musculoaponeurotic structures throughout the body. The exact cause still remains unknown, however, they may present sporadically or as a manifestation of a hereditary syndrome called familial adenomatous polyposis (FAP). Although they lack the capacity to establish metastases, DTs/AF may be devastated and occasionally fatal. As a result of the heterogeneity of DTs/AF, treatment needs to be individualized to improve local tumor control and maintain patients’ quality of life. Therefore, after a multidisciplinary approach, all treatment options should be discussed with patients. Where systemic chemotherapy has been shown to be unsuccessful with marked side effects in case of advanced DTs/AF, new therapeutic options are needed. Methods A Medline search was conducted and published articles in different studies from 2000 to the present were reviewed. Conclusion More research is needed to illustrate both the prognostic and predictive factors of the targeted therapy and the value of their combinations with or without other treatment modalities to get the best result for the treatment of advanced DTs/AF.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"11 1","pages":"9 - 16"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Forum of Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/fco-2019-0023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

Abstract

Abstract Background Desmoid tumors/aggressive fibromatosis (DTs/AF) are cytological bland fibrous neoplasms originating from the musculoaponeurotic structures throughout the body. The exact cause still remains unknown, however, they may present sporadically or as a manifestation of a hereditary syndrome called familial adenomatous polyposis (FAP). Although they lack the capacity to establish metastases, DTs/AF may be devastated and occasionally fatal. As a result of the heterogeneity of DTs/AF, treatment needs to be individualized to improve local tumor control and maintain patients’ quality of life. Therefore, after a multidisciplinary approach, all treatment options should be discussed with patients. Where systemic chemotherapy has been shown to be unsuccessful with marked side effects in case of advanced DTs/AF, new therapeutic options are needed. Methods A Medline search was conducted and published articles in different studies from 2000 to the present were reviewed. Conclusion More research is needed to illustrate both the prognostic and predictive factors of the targeted therapy and the value of their combinations with or without other treatment modalities to get the best result for the treatment of advanced DTs/AF.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
晚期硬纤维瘤的靶向治疗现状
摘要背景Desmoid肿瘤/侵袭性纤维瘤病(DTs/AF)是一种起源于全身肌肉筋膜结构的细胞学平淡的纤维肿瘤。确切的病因仍然未知,然而,它们可能偶尔出现,或作为一种称为家族性腺瘤性息肉病(FAP)的遗传综合征的表现。尽管DTs/AF缺乏建立转移的能力,但它们可能会被破坏,偶尔会致命。由于DTs/AF的异质性,需要对治疗进行个体化,以改善局部肿瘤控制并维持患者的生活质量。因此,在采用多学科方法后,应与患者讨论所有治疗方案。在晚期DTs/AF的情况下,全身化疗被证明是不成功的,并且有明显的副作用,需要新的治疗方案。方法对2000年至今不同研究中发表的文献进行Medline检索。结论需要更多的研究来阐明靶向治疗的预后和预测因素,以及它们与其他治疗方式或不与其他治疗模式相结合的价值,以获得治疗晚期DTs/AF的最佳结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Forum of Clinical Oncology
Forum of Clinical Oncology Medicine-Oncology
CiteScore
0.50
自引率
0.00%
发文量
3
审稿时长
6 weeks
期刊最新文献
Breast cancer recurrence and tumor size: A bibliometric analysis Outcomes of patients with localized prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy boost: A single-center retrospective study Glomerulonephritis as a paraneoplastic event from prostate cancer relapse Change of dosing paradigm in oncology Total neoadjuvant therapy in rectal cancer: a review across studies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1